IP Verse

Astrazeneca competitive analysis

Loading summary...

Latest patents of Astrazeneca opposed by its competitors

Explore Astrazeneca's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4188389
Sep 17, 2025Methods Of Treating Chronic Kidney Disease With Dapagliflozin1
EP3045466
Oct 16, 2024(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes1
EP4175619
Apr 10, 2024Compositions, Methods And Systems For Aerosol Drug Delivery2
EP4175620
Apr 10, 2024Compositions, Methods And Systems For Aerosol Drug Delivery1
EP4197528
Apr 3, 2024Compositions, Methods And Systems For Aerosol Drug Delivery1
EP2341905
Sep 13, 2023Sustained Release Formulations Using Non-Aqueous Carriers1
EP4114465
Aug 30, 2023Anti-Ifnar1 Dosing Regime For Subcutaneous Injection1
EP2508188
May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate5
EP3769781
Apr 19, 2023Stable Anti-Ifnar1 Formulation1
EP2785349
Nov 9, 2022Combination Treatment Of Cancer1

Latest publications and patents of Astrazeneca New

Explore the latest publications and patents granted to Astrazeneca, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Astrazeneca

EP4188389
Sep 17, 2025Methods Of Treating Chronic Kidney Disease With DapagliflozinGranted And Under Opposition
EP3045466
Oct 16, 2024(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of DiabetesPatent Maintained As Amended
EP4175620
Apr 10, 2024Compositions, Methods And Systems For Aerosol Drug DeliveryGranted And Under Opposition
EP4175619
Apr 10, 2024Compositions, Methods And Systems For Aerosol Drug DeliveryGranted And Under Opposition
EP4197528
Apr 3, 2024Compositions, Methods And Systems For Aerosol Drug DeliveryGranted And Under Opposition
EP2341905
Sep 13, 2023Sustained Release Formulations Using Non-Aqueous CarriersPatent Maintained As Amended
EP4114465
Aug 30, 2023Anti-Ifnar1 Dosing Regime For Subcutaneous InjectionGranted And Under Opposition
EP2508188
May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol HydrateGranted And Under Opposition
EP3769781
Apr 19, 2023Stable Anti-Ifnar1 FormulationGranted And Under Opposition
EP2785349
Nov 9, 2022Combination Treatment Of CancerPatent Maintained As Amended

Latest PTAB cases involving Astrazeneca

Discover the latest PTAB cases involving Astrazeneca, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Astrazeneca

IPR2017-01910Aug 4, 2017FRESENIUS KABI USAASTRAZENECA ABInstitution Denied
IPR2017-01912Aug 4, 2017FRESENIUS KABI USAASTRAZENECA ABInstitution Denied
IPR2017-01913Aug 4, 2017FRESENIUS KABI USAASTRAZENECA ABInstitution Denied
IPR2017-00900Feb 17, 2017INNOPHARMA LICENSINGASTRAZENECA ABInstitution Denied
IPR2017-00904Feb 17, 2017INNOPHARMA LICENSINGASTRAZENECA ABInstitution Denied
IPR2017-00905Feb 17, 2017INNOPHARMA LICENSINGASTRAZENECA ABInstitution Denied
IPR2017-00631Jan 9, 2017COMPLEX INNOVATIONSASTRAZENECA ABInstitution Denied
IPR2016-01316Jun 29, 2016MYLAN PHARMACEUTICALSASTRAZENECA ABTerminated-Settled
IPR2016-01324Jun 29, 2016MYLAN PHARMACEUTICALSASTRAZENECA ABTerminated-Settled
IPR2016-01325Jun 29, 2016MYLAN PHARMACEUTICALSASTRAZENECA ABInstitution Denied

Peer Comparison New

IP litigation analysis comparing Astrazeneca with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ASTRAZENECA - 27 - -
GALENICUM HEALTH SLU2713 - -
GEDEON RICHTER3 - - -
GENERICS UK214 - - -